Skip to content
  • Facebook
  • Twitter
  • Instagram
  • Email

ORCHESTRA Cohort

A Horizon 2020 cohort

  • Project
  • Community
  • Contact

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

LMU Klinikum München, Abteilung für Infektions- und Tropenmedizin (Tropeninstitut): Die Phase 1 - Studie eines Corona-Impfstoffes wird in eigens dafür bereitgestellten Räumen durchgeführt.

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

09.10.2023

Copyright: LMU Hospital Munich

 

In a recent study, ORCHESTRA researchers within the KoCo19 Study of the LMU University Hospital Munich and partners, looked at how our immune systems respond to COVID-19 in different situations: after getting infected, after being vaccinated, or if someone got infected even after vaccination (called “breakthrough infections”). They measured a specific type of immune response called “anti-spike antibodies” for 18 months after infection using a standardized method. They found that people who had been sick with COVID-19 had varying levels of these antibodies, making it a difficult to measure their protection accurately, especially several months after the infection. However, those who were vaccinated without prior infection showed more consistent results.

 

“These findings are important because they help us understand how our bodies respond to COVID-19 and how to measure that response”, PD Dr. med Inge Kroidl, one of the Principal Investigators of the Koco19 Immu Study, says. “It’s challenging to set a clear standard for protection or booster shots based on these measurements due to the differences in tests and the time that has passed since infection.” This information is vital for public health decisions and will also guide scientists and developers in improving tests and recommendations. Find the original study here:

https://virologyj.biomedcentral.com/articles/10.1186/s12985-023-02167-z

###

ORCHESTRA has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No 101016167.

Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic
EU Call: H2020-SC1-PHE-CORONAVIRUS-2020-2-RTD
Start date: 1 December 2020   End date: 30 November 2024
Coordinated by: UNIVERSITA DEGLI STUDI DI VERONA

© 2024 Orchestra. All right reserved.   Privacy Policy   Imprint